Edition:
India

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,765JPY
14 Aug 2020
Change (% chg)

¥-2 (-0.11%)
Prev Close
¥1,767
Open
¥1,781
Day's High
¥1,781
Day's Low
¥1,756
Volume
3,446,000
Avg. Vol
5,144,783
52-wk High
¥1,987
52-wk Low
¥1,404

Select another date:

Tue, Aug 11 2020

Photo

Bayer takes on Astellas in purchase of experimental menopause relief

FRANKFURT Bayer moved to acquire a prospective non-hormonal menopause relief for an initial $425 million to strengthen its women's healthcare business, in a challenge to a similar development venture at Astellas .

UPDATE 2-Bayer takes on Astellas in purchase of experimental menopause relief

* Gynaecology unit suffered from litigation, generic competition (Releads, adds rival project, M&A strategy)

BRIEF-Astellas Pharma Says Final Prosper Results Show Xtandi Significantly Extends Overall Survival In Men With Non-Metastatic Castration-Resistant Prostate Cancer

* FINAL PROSPER RESULTS SHOW XTANDI SIGNIFICANTLY EXTENDS OVERALL SURVIVAL IN MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Source text for Eikon: Further company coverage:

BRIEF-FDA Approves First Treatment For A Form Of Bladder Dysfunction In Patients As Young As 2 Yrs Of Age

* FDA APPROVES FIRST TREATMENT FOR A FORM OF BLADDER DYSFUNCTION IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OF AGE

BRIEF-Astellas Pharma Says European Medicines Agency Accepts Astellas' Marketing Authorization Application For Roxadustat

* ASTELLAS PHARMA INC - EUROPEAN MEDICINES AGENCY ACCEPTS ASTELLAS' MARKETING AUTHORIZATION APPLICATION FOR ROXADUSTAT Source text for Eikon: Further company coverage:

BRIEF-Cytokinetics - Co, Astellas Pharma Entered Two Agreements, Which Amend And Restate Co's Research, Development Commercialization Collaboration

* CYTOKINETICS - CO, ASTELLAS PHARMA INC. ENTERED TWO AGREEMENTS, WHICH AMEND AND RESTATE CO'S RESEARCH, DEVELOPMENT COMMERCIALIZATION COLLABORATION

BRIEF-Astellas Pharma Announces Acceptance Of Xospata For Regulatory Review In China By National Medical Products Administration

* ASTELLAS PHARMA INC ANNOUNCES ACCEPTANCE OF XOSPATA (GILTERITINIB) FOR REGULATORY REVIEW IN CHINA BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Amgen Establishes Wholly-Owned Affiliate In Japan

* CONSUMMATED PURCHASE FROM ASTELLAS OF 49% OF SHARES OF AMGEN ASTELLAS BIOPHARMA K.K., JOINT VENTURE BETWEEN CO AND ASTELLAS Source text for Eikon: Further company coverage:

BRIEF-Cytomx Therapeutics Says Co And Astellas Announce Strategic Collaboration

* CYTOMX THERAPEUTICS AND ASTELLAS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP PROBODY® T-CELL ENGAGING BISPECIFIC THERAPIES FOR TREATMENT OF CANCER

BRIEF-Seattle Genetics & Astellas Receive FDA Breakthrough Therapy Designation For Padcev In Combination With Pembrolizumab In 1st-Line Advanced Bladder Cancer

* SEATTLE GENETICS AND ASTELLAS RECEIVE FDA BREAKTHROUGH THERAPY DESIGNATION FOR PADCEV™ (ENFORTUMAB VEDOTIN-EJFV) IN COMBINATION WITH PEMBROLIZUMAB IN FIRST-LINE ADVANCED BLADDER CANCER

Select another date: